Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Ipilimumab in combination with Nivolumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Opdivo (nivolumab) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.